
Five9 Inc. (FIVN) reported robust Q2 2025 results, achieving 12% year-over-year revenue growth to $283 million and an all-time high adjusted EBITDA margin of 24%, significantly bolstered by a 42% surge in enterprise AI revenue and a strong enterprise-focused strategy. Despite these solid operational and strategic advancements, including a 108% dollar-based retention rate, the stock declined 5.28% in regular trading. The company projects continued profitability and growth, targeting a 'Rule of 40+' by 2027, highlighting its competitive positioning in the cloud contact center market.
Five9 Inc. (FIVN) demonstrated strong operational execution in its Q2 2025 results, yet faced a negative market reaction with its stock declining 5.28%. The company reported a 12% year-over-year revenue increase to $283 million, driven by a 16% growth in subscription revenue, and achieved a record-high 24% adjusted EBITDA margin, reflecting a 63% YoY surge in adjusted EBITDA dollars. A key growth catalyst is the company's artificial intelligence business, where enterprise AI revenue grew 42% YoY and now constitutes over 20% of new enterprise logo bookings. This AI traction, combined with a successful enterprise-focused strategy now accounting for 90% of total revenue and a robust 108% dollar-based retention rate, underscores fundamental strength. The company's guidance for Q3 revenue of $283.0-$286.0 million suggests minimal sequential growth from the current quarter, which may have contributed to the stock's decline despite the strong performance and positive medium-term outlook targeting a "Rule of 40+" by 2027. Financially, the reduction in cash to $635.9 million was a result of a strategic $434.4 million debt repayment, improving the balance sheet rather than indicating operational strain, which is further supported by a positive 8% free cash flow margin.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment